Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis-Reference-Cited by-同舟云学术

Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis

Published:2021-01-01 Issue:1 Volume:10 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Abdelrahim Maen¹,Mamlouk Omar²,Lin Heather³,Lin Jamie²,Page Valda²,Abdel-Wahab Noha⁴⁵⁶,Swan Joshua⁷,Selamet Umut⁸,Yee Cassian⁶,Diab Adi⁶,Suki Wadi⁹,Abudayyeh Ala²

Affiliation:

1. Institute of Academic Medicine and Weill Cornell Medical College, Houston Methodist Cancer Center, Houston, Texas, USA

2. Section of Nephrology, Division of Internal Medicine, Section of Nephrology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

3. Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

4. Rheumatology and Rehabilitation Department, Assiut University Hospitals, Faculty of Medicine, Assiut, Egypt

5. Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

6. Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA

7. Department of System Pharmacy, Houston Methodist, Houston, Texas, USA

8. Division of Renal Medicine, Brigham and Women’s Hospital, Boston, Massachusetts, USA

9. Department of Medicine, Nephrology, Houston Methodist Hospital, Houston, Texas, USA

Funder

National Institutes of Health/National Cancer Institute

the University of Texas MD Anderson Cancer Center Division of Internal Medicine Immuno-Oncology Toxicity Award Program

University of Texas MD Anderson Cancer Center Division of Internal Medicine Immuno-Oncology Toxicity Award Program

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2021.1927313

Reference41 articles.

1. Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma

2. Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs

3. Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review

4. Autoimmunity Correlates With Tumor Regression in Patients With Metastatic Melanoma Treated With Anti–Cytotoxic T-Lymphocyte Antigen-4

5. Prognostic Factors Related to Clinical Response in Patients with Metastatic Melanoma Treated by CTL-Associated Antigen-4 Blockade

Cited by 33 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Analysis of Risk Factors and the Establishment of a Predictive Model for Thrombosis in Patients with immune thrombocytopenia;2024-08-22

2. Bibliometric and visual analysis of immunisation associated with acute kidney injury from 2003 to 2023;Frontiers in Pharmacology;2024-07-01

3. Development and validation of a nomogram for predicting the occurrence of renal dysfunction after treatment of immune checkpoint inhibitor: a retrospective case–control study;BMJ Open;2024-05

4. Interpretable machine learning-based individual analysis of acute kidney injury in immune checkpoint inhibitor therapy;PLOS ONE;2024-03-19

5. Immunosuppressants against acute kidney injury: what to prefer or to avoid?;Immunopharmacology and Immunotoxicology;2024-03-18